State-of-the-art strategies for targeting the DNA damage response in cancer
Genomic instability is a key hallmark of cancer that arises owing to defects in the DNA
damage response (DDR) and/or increased replication stress. These alterations promote the …
damage response (DDR) and/or increased replication stress. These alterations promote the …
The plasticity of DNA replication forks in response to clinically relevant genotoxic stress
Complete and accurate DNA replication requires the progression of replication forks through
DNA damage, actively transcribed regions, structured DNA and compact chromatin. Recent …
DNA damage, actively transcribed regions, structured DNA and compact chromatin. Recent …
DNA damage checkpoint kinases in cancer
HL Smith, H Southgate, DA Tweddle… - Expert reviews in …, 2020 - cambridge.org
DNA damage response (DDR) pathway prevents high level endogenous and environmental
DNA damage being replicated and passed on to the next generation of cells via an …
DNA damage being replicated and passed on to the next generation of cells via an …
[HTML][HTML] Combined TP53 and RB1 loss promotes prostate cancer resistance to a spectrum of therapeutics and confers vulnerability to replication stress
MD Nyquist, A Corella, I Coleman, N De Sarkar… - Cell reports, 2020 - cell.com
Prostate cancers (PCs) with loss of the potent tumor suppressors TP53 and RB1 exhibit poor
outcomes. TP53 and RB1 also influence cell plasticity and are frequently lost in PCs with …
outcomes. TP53 and RB1 also influence cell plasticity and are frequently lost in PCs with …
Targeting ATR in cancer
E Lecona, O Fernandez-Capetillo - Nature Reviews Cancer, 2018 - nature.com
The chemical treatment of cancer started with the realization that DNA damaging agents
such as mustard gas present notable antitumoural properties. Consequently, early drug …
such as mustard gas present notable antitumoural properties. Consequently, early drug …
ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells
SA Yazinski, V Comaills, R Buisson… - Genes & …, 2017 - genesdev.cshlp.org
Poly-(ADP-ribose) polymerase (PARP) inhibitors (PARPis) selectively kill BRCA1/2-deficient
cells, but their efficacy in BRCA-deficient patients is limited by drug resistance. Here, we …
cells, but their efficacy in BRCA-deficient patients is limited by drug resistance. Here, we …
ATR/CHK1 inhibitors and cancer therapy
Z Qiu, NL Oleinick, J Zhang - Radiotherapy and Oncology, 2018 - Elsevier
The cell cycle checkpoint proteins ataxia-telangiectasia-mutated-and-Rad3-related kinase
(ATR) and its major downstream effector checkpoint kinase 1 (CHK1) prevent the entry of …
(ATR) and its major downstream effector checkpoint kinase 1 (CHK1) prevent the entry of …
Exploiting DNA replication stress for cancer treatment
Complete and accurate DNA replication is fundamental to cellular proliferation and genome
stability. Obstacles that delay, prevent, or terminate DNA replication cause the phenomena …
stability. Obstacles that delay, prevent, or terminate DNA replication cause the phenomena …
Homologous recombination deficiency: cancer predispositions and treatment implications
MR Toh, J Ngeow - The oncologist, 2021 - academic.oup.com
Homologous recombination (HR) is a highly accurate DNA repair mechanism. Several HR
genes are established cancer susceptibility genes with clinically actionable pathogenic …
genes are established cancer susceptibility genes with clinically actionable pathogenic …
Targeting the ATR-CHK1 axis in cancer therapy
S Rundle, A Bradbury, Y Drew, NJ Curtin - Cancers, 2017 - mdpi.com
Targeting the DNA damage response (DDR) is a new therapeutic approach in cancer that
shows great promise for tumour selectivity. Key components of the DDR are the ataxia …
shows great promise for tumour selectivity. Key components of the DDR are the ataxia …